Third-Party Multipotent Adult Progenitor Cells as a Novel Cell Therapy in Solid Organ Transplantation
Elke Eggenhofer(University Hospital Regensburg), Marc-Hendrik Dahlke, Philipp Renner(Robert Bosch Hospital), Wouter Van’t Hof(Athersys (United States)), EK Geissler(University Hospital Regensburg), Barbara Fillenberg, Michael Mendicino(Athersys (United States)), R. Deans(Athersys (United States)), H. J. Schlitt(Medizinische Hochschule Hannover), Felix Popp(University of Regensburg)
Cited by 0
Related Papers
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion
|Frontiers in Immunology|2012|820
Immunomodulatory Effects of Mesenchymal Stem Cells in a Rat Organ Transplant Model
|Transplantation|2006|255
Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate
|Transplant Immunology|2008|198
Urinary Biomarkers TIMP-2 and IGFBP7 Early Predict Acute Kidney Injury after Major Surgery
|PLoS ONE|2015|169
Mesenchymal Stem Cells Require a Sufficient, Ongoing Immune Response to Exert Their Immunosuppressive Function
|Transplantation Proceedings|2009|124